CNS-invasive aspergillosis following ibrutinib therapy
- 8 December 2022
- journal article
- Published by Peertechz Publications Private Limited in International Journal of Immunotherapy and Cancer Research
- Vol. 8 (1), 001-003
- https://doi.org/10.17352/2455-8591.000035
Abstract
Ibrutinib is Bruton’s tyrosine kinase inhibitor that now become the standard of care for the treatment of CLL (chronic lymphocytic leukemia) and other lymphoid cancers. With its increasing usage, oncologists must become more aware of their potential side effect profile. Ibrutinib is typically thought to be less immunosuppressive than standard immunotherapy; however, can still cause devastating side effects. We present a case of CNS-invasive aspergillosis in a patient with Waldenstrom’s macroglobulinemia being managed with ibrutinib. We hypothesize that treatment with ibrutinib can resemble those with X-gammaglobulinemia, thus putting our patient at risk of developing such an invasive fungal infection. Traditional risk factors for CNS-invasive aspergillosis include neutropenia, systemic glucocorticoid treatment, mastoidectomy, spinal anesthesia and paraspinal glucocorticoid injections. Oncologists need to weigh the risks and benefits of ibrutinib therapy in certain populations and more data in the future may suggest potentially adding empiric antifungal coverage with its usage.Keywords
This publication has 19 references indexed in Scilit:
- Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functionsBlood, 2014
- PCR in Diagnosis of Invasive Aspergillosis: a Meta-Analysis of Diagnostic PerformanceJournal of Clinical Microbiology, 2014
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytesBlood, 2013
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2013
- Aspergillus meningitis: A rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 casesJournal of Infection, 2012
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemiaBlood, 2012
- Clinical risk factors for invasive aspergillosisMedical Mycology, 2011
- Update on invasive aspergillosis: clinical and diagnostic aspectsClinical Microbiology & Infection, 2006
- Poster Sessions I and II , Interdisciplinary Workshop, Satelite Symposia I-IVAnnals of Hematology, 2004
- Role of Bruton's Tyrosine Kinase in B Cell DevelopmentDevelopmental Immunology, 2001